-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Benzinga·03/17/2026 12:25:10
Listen to the news
Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price target.